Humans Male *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures

Humans *Carcinoma Transitional Cell/radiotherapy/surgery/drug therapy *Urinary Bladder Neoplasms Radiotherapy Adjuvant Retrospective Studies Prospective Studies Neoplasm Recurrence Local adjuvant radiotherapy external beam genitourinary locoregional control meta-analysis proximal ureter renal pelvis survival systematic review upper tract urothelial carcinoma

Animals Dietary Supplements Humans Nitroso Compounds/*administration & dosage Risk Factors Urinary Bladder Neoplasms/*diagnosis Bladder Dietary Neoplasms Nitrate Nitrite Nitrosamines Organic chemicals

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy

*Cystectomy Humans *Neoadjuvant Therapy Neoplasm Staging Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/pathology/*surgery

Carcinoma Transitional Cell/*pathology/*surgery Humans Kidney Neoplasms/*pathology Neoplasms Second Primary/*pathology Nephrotomy Risk Factors Stents/*adverse effects Ureteral Obstruction/etiology/*surgery Urinary Bladder Neoplasms/*pathology/*surgery carcinoma transitional cell hydronephrosis meta-analysis stents urinary bladder neoplasms

Biomarkers Humans Inflammation Prognosis Proportional Hazards Models *Urinary Bladder Neoplasms bladder cancer meta-analysis survival systemic immune-inflammation index commercial or financial relationships that could be construed as a potential conflict of interest.

*Carcinoma Transitional Cell Case-Control Studies Epidemiologic Studies Female Folic Acid Humans Male Prospective Studies Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology/prevention & control

*Cystectomy/adverse effects Humans Postoperative Complications/epidemiology/etiology Prospective Studies Retrospective Studies *Robotic Surgical Procedures/adverse effects *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery Bladder cancer Intracorporeal Meta-analysis Radical cystectomy Robot-assisted

Humans Male *Urinary Bladder Neoplasms Reproducibility of Results ROC Curve Image Interpretation Computer-Assisted Muscles Magnetic Resonance Imaging Retrospective Studies Bladder cancer Inter-reader agreement Meta-analysis Reliability Vi-rads

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

Cystectomy/adverse effects Female Humans Male Network Meta-Analysis *Urinary Bladder Neoplasms/pathology/surgery Urologic Surgical Procedures Tueb Turbt bladder cancer en bloc transurethral en bloc transurethral resection

*Cystectomy Humans Prospective Studies Systematic Reviews as Topic Treatment Outcome Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/pathology/surgery models mortality nomograms radical cystectomy urinary bladder neoplasms

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Administration Intravesical *Carcinoma Transitional Cell/pathology Humans Male Neoplasm Invasiveness/pathology Neoplasm Recurrence Local/pathology Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/therapy

Humans *Carcinoma Transitional Cell/diagnosis/therapy *Urinary Bladder Neoplasms Systematic Reviews as Topic Kidney Oregon *Ureteral Neoplasms/diagnosis/therapy Utuc renal pelvis cancer upper tract urothelial cancer ureteral cancer urothelial cancer

*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

Area Under Curve Female Humans Male Neoplasm Recurrence Local/diagnosis Prospective Studies Recurrence Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnosis Biomarker Bladder cancer Diagnostic accuracy Systematic review Xpert